Pittsburgh plasma p‐tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer's disease in the community
Anuradha Sehrawat(University of Pittsburgh), Thomas K. Karikari(University of Pittsburgh)
Cited by 7
Related Papers
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
|The Lancet Neurology|2020|1.3k
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
|JAMA Neurology|2021|627
A multicentre validation study of the diagnostic value of plasma neurofilament light
|Nature Communications|2021|554
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected
|EMBO Molecular Medicine|2020|411
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
|Alzheimer s & Dementia|2021|354